Northern Trust Corp Has $37.95 Million Stock Holdings in Bruker Corporation $BRKR

Key Points

• Northern Trust Corp reduced its stake in Bruker Corporation by 1.2%, selling 11,406 shares and retaining approximately 0.60% ownership worth $37.95 million.
• The company recently reported earnings per share of $0.32 for the quarter, missing the consensus estimate of $0.33, with revenue of $797.40 million, below the expected $811.17 million.
• Analysts have mixed ratings for Bruker, with five giving a "Buy" rating, six issuing a "Hold," and an average price target of $51.30, down from previous estimates.

Northern Trust Corp trimmed its stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 1.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 909,181 shares of the medical research company's stock after selling 11,406 shares during the quarter. Northern Trust Corp owned approximately 0.60% of Bruker worth $37,949,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of BRKR. Pinnacle Bancorp Inc. acquired a new position in shares of Bruker during the first quarter worth $29,000. Allworth Financial LP lifted its holdings in Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock worth $30,000 after buying an additional 364 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock worth $33,000 after buying an additional 745 shares during the period. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Bruker in the 1st quarter valued at about $42,000. Finally, MassMutual Private Wealth & Trust FSB increased its stake in shares of Bruker by 274.9% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after buying an additional 800 shares during the period. Institutional investors own 79.52% of the company's stock.

Bruker Stock Down 11.7%

Shares of Bruker stock traded down $3.88 during trading on Wednesday, reaching $29.35. 18,323,888 shares of the company traded hands, compared to its average volume of 2,747,442. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $72.94. The company has a 50 day moving average price of $37.59 and a 200-day moving average price of $39.96. The firm has a market capitalization of $4.45 billion, a PE ratio of 56.44, a P/E/G ratio of 2.79 and a beta of 1.21.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. During the same quarter in the previous year, the firm earned $0.52 EPS. The firm's revenue was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, equities research analysts expect that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be issued a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a yield of 0.7%. Bruker's dividend payout ratio is presently 38.46%.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien acquired 2,608 shares of the stock in a transaction on Friday, June 6th. The shares were purchased at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the acquisition, the chief executive officer owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. This represents a 0.01% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 27.30% of the company's stock.

Analyst Upgrades and Downgrades

BRKR has been the topic of several recent analyst reports. UBS Group dropped their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Barclays dropped their price objective on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Monday, August 4th. The Goldman Sachs Group decreased their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Jefferies Financial Group set a $60.00 target price on Bruker and gave the stock a "buy" rating in a report on Monday, August 4th. Finally, Bank of America lowered their target price on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Five research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, Bruker currently has a consensus rating of "Hold" and a consensus target price of $51.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.